Abbott Laboratories
ABT
$135.77
-$0.24-0.18%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 8.16% | 478.98% | 14.62% | -5.31% | -7.06% |
| Total Depreciation and Amortization | -6.09% | -0.74% | -2.79% | 0.63% | -0.12% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -4.93% | 147.08% | 0.00% | 6.82% | 8.19% |
| Change in Net Operating Assets | 27.20% | -2,084.91% | 128.20% | 73.91% | -3.72% |
| Cash from Operations | 38.24% | -5.60% | 44.11% | 62.93% | -10.32% |
| Capital Expenditure | -21.61% | 4.64% | 0.71% | -5.13% | -4.74% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -97.50% | -- |
| Other Investing Activities | 151.85% | -111.59% | -65.22% | -1.25% | 67.07% |
| Cash from Investing | -10.59% | -5.10% | 6.31% | 62.65% | 8.01% |
| Total Debt Issued | -- | -95.45% | -- | 22,000.00% | -- |
| Total Debt Repaid | -716.54% | 36.11% | 102.79% | -654.55% | -202.38% |
| Issuance of Common Stock | 114.18% | -26.47% | 64.29% | -13.33% | 116.13% |
| Repurchase of Common Stock | -23.89% | -21.62% | -37,450.00% | 99.30% | 58.15% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -7.21% | -7.88% | -8.11% | -7.98% | -7.53% |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -74.74% | 9.31% | 32.65% | 38.63% | 16.60% |
| Foreign Exchange rate Adjustments | 166.67% | -432.00% | 224.14% | 51.85% | -550.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -77.12% | -68.98% | 150.71% | 153.02% | 15.12% |